MedTrace Logo

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

NCT05392764 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 444

Last updated 2026-02-13

No results posted yet for this study

Summary

The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Empagliflozin 10 MG

once-daily oral empagliflozin 10 mg

DRUG

Placebo

Placebo matching empagliflozin 10 mg

Sponsors & Collaborators

Principal Investigators

  • Yuya Matsue, MD · Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-10
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05392764 on ClinicalTrials.gov